28
Apr

Just two months after raising $84 million from an upsized IPO, Concert Pharmaceuticals says that a key Phase II study of its lead drug–CTP-499–flopped on its primary endpoint for diabetic kidney disease.

…read more

Source: On heels of an IPO, Concert’s kidney drug flops in PhII

    

0 No comments